Rare Diseases / Respiratory › Cystic Fibrosis

AI-Driven Benefit-Risk Analysis for Cystic Fibrosis

Cystic fibrosis BRA spans CFTR modulators, next-generation correctors, and emerging gene therapies. ArcaScience delivers genotype-specific safety profiling across elexacaftor/tezacaftor/ivacaftor (Trikafta), lumacaftor/ivacaftor, and investigational gene therapy platforms—with hepatotoxicity monitoring, CYP3A interaction modeling, and pediatric long-term safety surveillance.

See Platform Request Demo

100,000+

CF patients globally

350+

CF clinical trials analyzed

$12B

Global CF therapeutics market

Transformed

CFTR modulators changed CF outcomes

Disease Overview

Why Cystic Fibrosis Demands Specialized BRA

CFTR modulator therapy has transformed cystic fibrosis from a fatal childhood disease to a chronic condition with dramatically improved life expectancy. This paradigm shift creates entirely new BRA challenges: hepatotoxicity in a population prone to CF-related liver disease, significant CYP3A drug interactions with common CF co-medications, pediatric age-lowering studies, and emerging long-term safety questions for a patient population with no historical precedent for extended survival.

Hepatotoxicity & CYP3A Interactions

CFTR modulators carry hepatotoxicity risk with ALT/AST elevations in 5-8% of Trikafta patients, complicated by pre-existing CF-related liver disease in up to 30% of patients. All CFTR modulators are CYP3A substrates, creating significant drug interaction risk with azole antifungals (used for ABPA), certain antibiotics, and hormonal contraceptives. BRA must model cumulative hepatic burden across the complex CF polypharmacy landscape.

Pediatric Cataracts & Mental Health

Non-congenital lens opacities and cataracts have been reported in pediatric patients on ivacaftor-containing regimens, requiring baseline and periodic ophthalmologic examinations. Additionally, depression and anxiety are increasingly recognized in adolescents and young adults on CFTR modulators, potentially related to the psychological adjustment of dramatically improved health status. These emerging signals require novel long-term pharmacovigilance approaches.

Fertility & Pregnancy Considerations

CFTR modulator therapy has restored fertility in many CF patients who historically had limited reproductive capacity. This creates urgent pregnancy safety questions: Trikafta animal reproductive studies show concerns, but discontinuing modulators during pregnancy risks maternal lung function decline. Limited pregnancy exposure data and the interaction between CFTR modulators and hormonal contraceptives via CYP3A make fertility-related BRA a critical unmet need.

Platform Capabilities

How ArcaScience Addresses CF BRA

Our platform integrates CF-specific CFTR modulator data, genotype-stratified efficacy models, hepatotoxicity monitoring algorithms, and regulatory templates aligned with FDA rare disease and EMA orphan medicinal product pathways.

Data Intelligence

CF CFTR Modulator Data

350+ CF clinical trials including VX-445 Phase 3 (Trikafta pivotal), EVOLVE, TRANSPORT, and STRIVE/ENVISION datasets. Integrated CF Foundation Patient Registry data, real-world evidence from Trikafta post-marketing surveillance, and genotype-phenotype correlation databases covering 2,000+ CFTR mutations with drug interaction databases mapped to common CF co-medications.

Explore Data Engine →

Decision Intelligence

Genotype-Stratified AI Models

AI models for genotype-specific CFTR modulator response prediction, hepatotoxicity risk scoring incorporating baseline liver function and CYP3A inhibitor co-administration, ppFEV1 trajectory modeling, drug-drug interaction severity estimation, and pediatric cataract risk stratification for ivacaftor-containing regimens in patients under 12 years of age.

Explore AI Models →

Automated Outputs

CF Regulatory Outputs

PSURs with genotype-stratified safety and efficacy analysis, RMPs incorporating hepatotoxicity monitoring protocols and CYP3A interaction management, label extension support for new genotype populations, pregnancy exposure registry reports, and pediatric ophthalmologic monitoring frameworks aligned with FDA rare disease and EMA orphan medicinal product pathways.

Explore Outputs →

CF Intelligence

Platform Performance in Cystic Fibrosis

2,400,000,000+

CF safety and efficacy data points

65%

Faster hepatotoxicity signal detection

2,000+

CFTR mutations mapped with modulator data

CF regulatory submissions supported

Case Evidence — Cystic Fibrosis

Pediatric CFTR Modulator Long-Term Safety Surveillance (Ages 2-5)

Challenge

A CFTR modulator manufacturer needed to support age-lowering from 6+ years to 2-5 years, requiring demonstration of favorable benefit-risk in a population where hepatotoxicity monitoring is more complex, cataract risk is of particular concern in developing eyes, and long-term exposure data is inherently limited by the recency of CFTR modulator availability.

Result

ArcaScience integrated Phase 3 pediatric trial data with CF Foundation Registry real-world evidence and extrapolated safety models from older age cohorts. The platform identified that hepatotoxicity rates in 2-5 year-olds were consistent with the 6-11 year cohort when weight-based dosing was applied, supporting the age-lowering approval. Cataract monitoring protocols were enhanced based on AI-detected age-at-exposure risk patterns.

58%

Faster pediatric BRA completion

2 yrs

Youngest approved age achieved

View All Case Studies →

Age-lowering submissions in CF are uniquely challenging because we are asking regulators to approve treatment in toddlers based on limited trial data extrapolated from older children. ArcaScience's ability to integrate our Phase 3 pediatric data with registry evidence and older-cohort safety models gave us the comprehensive BRA narrative the FDA required. The cataract risk stratification was particularly valuable for our label recommendations.

Director of CF Clinical Development

Specialty Pharma Company

Frequently Asked Questions

Cystic Fibrosis Benefit-Risk Analysis

Our platform integrates Phase 3 pediatric trial data with age-stratified safety extrapolation models from older cohorts (12+, 6-11, 2-5 years). We model weight-based dosing impact on hepatotoxicity rates, pediatric-specific cataract risk by age-at-exposure, developmental milestone tracking alongside safety endpoints, and the unique benefit assessment of early CFTR modulator initiation before irreversible lung damage occurs. This comprehensive framework supports pediatric study plan (PSP) and pediatric investigation plan (PIP) submissions.

Pregnancy in CF patients on CFTR modulators is a rapidly emerging clinical reality. Our platform aggregates pregnancy exposure registry data, preclinical reproductive toxicology findings, and emerging real-world pregnancy outcomes from CF Foundation and international registries. BRA models weigh the risk of CFTR modulator exposure during pregnancy against the documented maternal lung function decline when modulators are discontinued, and the impact of CYP3A-mediated interactions on hormonal contraceptive efficacy. This supports regulatory pregnancy category decisions and clinical guidance development.

Our platform models hepatotoxicity risk incorporating baseline CF-related liver disease status, concurrent CYP3A inhibitor use (azole antifungals for ABPA are particularly common), age-specific ALT/AST patterns, and the cumulative hepatic impact of lifelong CFTR modulator therapy. AI models provide individualized hepatotoxicity risk scores that inform monitoring frequency recommendations, dose modification triggers, and the benefit-risk balance of continuing therapy in patients with elevated transaminases versus the risk of CF lung disease progression if modulators are stopped.

Gene therapy for CF is in clinical development with both viral vector (AAV) and non-viral (lipid nanoparticle mRNA) approaches. Our platform models the unique BRA challenges of gene therapy in the CF lung environment: pre-existing anti-AAV antibodies from prior viral exposures, immune responses to vector readministration, the durability of CFTR expression versus the need for repeated dosing, and the interaction between gene therapy and ongoing CFTR modulator use during the transition period. We support IND-enabling BRA for first-in-human gene therapy studies.

Yes. Our platform integrates three evidence layers for rare genotype BRA: in vitro CFTR function data from cell-based chloride transport assays, clinical trial data stratified by genotype from pivotal trials, and real-world evidence from CF Foundation Patient Registry and international registries. AI models correlate in vitro CFTR rescue levels with clinical ppFEV1 improvement and sweat chloride reduction, enabling benefit-risk estimation even for ultra-rare mutations present in fewer than 50 patients globally. This approach supported the label extension covering 26 additional rare CFTR mutations.

See ArcaScience Applied to Cystic Fibrosis

Request a demonstration of ArcaScience's platform configured for cystic fibrosis benefit-risk analysis. Our rare disease scientists will walk through genotype-stratified models, hepatotoxicity monitoring frameworks, pediatric age-lowering BRA, and gene therapy safety modeling examples.

Request CF Briefing Explore the Platform →